CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23,789 enrolled
Drug / intervention
3 drug dose - IDA +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02899936
NCT02899936N/ACompleted
CompareCT.gov

Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis

Washington University School of Medicine·interventional·Posted Sep 14, 2016·Updated Dec 31, 2020

In Brief

A clinical study evaluating 3 drug dose - IDA and 2 drug dose - DA for Lymphatic Filariasis. Completed, enrolled 23,789 participants across 4 sites in 4 countries.

Detailed Summary

The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community in 5 different countries. The objective is to acquire safety, efficacy, and acceptability data to assess the safety and acceptability of the IDA drug combination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphatic Filariasis
CountriesHaiti, India, Indonesia, Papua New Guinea
CollaboratorsCase Western Reserve University, Indian Council of Medical Research

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 14, 2016
Enrollment StartJul 1, 2016
Primary CompletionApr 27, 2017
Study CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.8 years ago

Interventions

3 drug dose - IDAdrug

Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)

2 drug dose - DAdrug

Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)